Skip to main content
OpenTrials

Clinical trial condition

Amyotrophic Lateral Sclerosis

Explore clinical trials studying Amyotrophic Lateral Sclerosis. Study availability and eligibility vary by location and protocol.

707 public trials 173 recruiting studies
Refine in advanced search Browse all conditions

Amyotrophic Lateral Sclerosis trial results

Active, Not Recruiting

ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

NCT05928416

Conditions
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic lateral sclerosis 1, +10 more
Locations
  • CHU Strasbourg Strasbourg, Alsace, France
  • CHU Nantes Saint-Herblain, Loire-Atlantique, France
  • C.H.U. de Saint-Étienne Saint-Étienne-de-Montluc, Pays de la Loire Region, France
  • Hospices Civils de Lyon Bron, Rhône, France
View all 19 locations
View Trial Details
Active, Not Recruiting

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • University of California Orange, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Augusta University Augusta, Georgia, United States
  • Indiana University IU Health Neuroscience Center Indianapolis, Indiana, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

ALS Phase II Study of NX210c

NCT06365216

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • Centre Hospitalier Regional Et Universitaire De Brest Brest, France
  • Centre Hospitalier Universitaire De Caen Normandie Caen, France
  • Hôpital La Timone - APHM Marseille, France
  • CHRU De Nancy Nancy, France
View all 16 locations
View Trial Details
Active, Not Recruiting

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

NCT05299658

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • Concord Hospital Concord, New South Wales, Australia
  • Neuroscience Research Australia Randwick, New South Wales, Australia
View Trial Details

Related conditions